Home/Telo Therapeutics/Mike Placke, Ph.D.

MP

Mike Placke, Ph.D.

Non-clinical Safety

Telo Therapeutics

Therapeutic Areas

Telo Therapeutics Pipeline

Drug	Indication	Phase
TSM74	Solid and Hematological Cancers (via XPO1 degradation)	Pre-clinical

Leadership Team at Telo Therapeutics

Robert Bell, Ph.D.

CEO & Co-Founder

Michael D Taylor, Ph.D.

Executive Chairman

Katherine Widdowson, Ph.D.

Preclinical Development

Glenn Michelson, MD

Clinical Development

Vassil Elitzin, Ph.D.

View full Telo Therapeutics profile